-
Melanoma "immune plus targeted" first-line treatment! Novarma partalizumab, Tafinlar, Mekinist combination Phase III clinical failure!
Time of Update: 2020-09-29
"While the COMBI-i trial did not reach its primary endpoint, the results provide us with valuable insights into the possible role of immunotherapy spartalizumab in future cancer combination therapies, and highlight the importance of previously identified Tafinlar-Mekinist targeted combination therapies for these patients," said Dr. John Tsai, Novart's director of global drug development and chief medical officer.
-
Advanced kidney cancer "targeted and immune" first-line treatment! BMS / Exelixis combination therapy Cabometyx and Opdivo apply for listing in the United States!
Time of Update: 2020-09-29
data show that in previously untreated patients with advanced RCC, the "target-immune" treatment Cabomyx-Opdivo combined significantly extended progressive survival (PFS), total survival (OS) and improved objective remission (ORR) compared to the first-line standard care drug Suttent (soltan, generic name: sunitinib, shonithini, a tyrosine kinase inhibitor developed by Pfizer).
-
The delivery of beva monoantigen affects the delivery of molybamine to improve the efficacy of treating recurring GBM.
Time of Update: 2020-09-29
MRI-PET scans using beva monoantitor and one month after use showed a decrease in tumor-reinforced volume, tymoamine absorption, cerebral blood flow perfusion pressure, and vascular permeability.
-
PD-1-CTLA-4 is once again creating a survival miracle: breaking the 15-year stalemate in thoracic mesothelioma without new drugs.
Time of Update: 2020-09-28
Recently, Checkmate-743 research results announced that The Navuliyu mono-Ipimu mono-resistance once again created a miracle of survival, can significantly improve the total survival of patients with previously untreated, non-removable malignant thoracic mesothelioma (OS), but also broke the deadlock of 15 years of no new drugs for thoracic mesothelioma.
-
"Nature" sub-journal review: "Cancer King" is difficult to deal with, where does immunotherapy get a breakthrough?
Time of Update: 2020-09-28
these multi-pictosant factors, so that the strategy of targeting T-cell immuno-checkpoint protein alone is not sufficient to reverse the immunosuppressive characteristics of tumor micro-environment.
-
The effect of immunotherapy is predicted by tumor antigen immune response or immune evasion function mutation.
Time of Update: 2020-09-28
Kwanel Kim, department of biology at Gyeongi University in Seoul, and others tried to predict the binding of peptides in major tissue compatible complexes (MHC) using convolutional neural networks (CNN) models, and developed classifiers that can predict tumor resistance from functional mutations, published online in February 2020.
-
Lung cancer is heavy! AstraZenecom Imfinzi (Infinfan) is approved by the European Union: first-line treatment of extensive stage small cell lung cancer (ES-SCLC)!
Time of Update: 2020-09-28
!--,2020 // -- AstraZeneca recently announced that the European Commission (EC) has approved anti-PD-L1 therapy Imfinzi (Infineon, generic name: durvalumab, dovalio monoanti), joint standard care (SoC) with platinum chemotherapy (etoposide plus carbatin or cisplatin), first-line treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC).
-
The world's first BCMA targeted therapy! GlaxoSmithKline Brenrep is approved by the European Union to treat relapse/recurring multiple myeloma!
Time of Update: 2020-09-28
http!--s webeditor: page.title-- August 28, 2020 / -- GlaxoSmithKline (GSK) recently announced that the European Commission (EC) has conditionally approved Blenrep (belantamab mafodotin, GSK2857916),
-
The study revealed the key role of manganese elements/manganese ions in tumor immunity.
Time of Update: 2020-09-28
addition, this study demonstrates that manganese element/manganese ions (Mn2 plus) play a vital role in anti-tumor immunity, opens up new ideas and treatment options for tumor immunotherapy (manganese-free therapy), and shows great clinical application prospects.
-
PNAS: New molecular markers help determine how cancer patients respond to immunotherapy.
Time of Update: 2020-09-27
(Photo: www.pixabay.com) In this study, scientists developed a way to implant breast cancer tumors in mice and treat them with immunosuppressants.
Chen el al., "A tumor model of contentional programs associated with patient response to immune checkpoint," PNAS (2020).
-
MRI dispersion imaging quantitatively predicts prognostication in patients with relapsed GBM.
Time of Update: 2020-09-27
ADClow's ability to predict overall patient survival (OS) and progress-free lifetime (PFS) was evaluated through biomarker threshold models and multivariable Cox regression analysis (Figure 1).
-
The three-drug association improved the prognosis of children with high-level gliomas.
Time of Update: 2020-09-26
the feasibility and safety of TIB treatment by recording toxic side reactions, DNA gene molecular spectrum and survival prognostics in pHGG patients during TIB treatment.
results, 36 children received TIB treatment, including 10 DIPG and 26 pHGG.
-
Cell: Identifying more than 7,000 genetic regions in the human genome that control the properties of blood cells is expected to predict the risk of rare and common blood diseases in the population.
Time of Update: 2020-09-26
September 10, 2020 // -- Now that two large-scale genetic studies have identified most of the genetic mutations that affect the important medical characteristics of the body's blood cells, scientists
-
The first in China! Junshi Bio-Anti-PD-1 Therapy Ripley Monoanti (Toyi ®) has been recognized by the FDA Breakthrough Therapy: Treatment of Nasopharyngeal Cancer!
Time of Update: 2020-09-26
In China, in April 2020, Junshi Bio's application to the State Drug Administration (NMPA) for the listing of a new adaptation of Ripley monoantigen for the treatment of relapsed and metastatic nasopharyngeal cancer that had previously failed to receive second-line and above system treatment was accepted and was included in the priority review process by NMPA in July.
-
Standardization of diagnostic reports on brain fluorescence in HGG surgery.
Time of Update: 2020-09-26
the authors point out that FGS diagnostic reporting standards need to ensure consistency and accuracy in the detail, recognition and description of biopsy conclusions.
-
The effect of laser interstational therapy on brain tumors.
Time of Update: 2020-09-26
Jianning Shao of the Lerner School of Medicine at Case Western Reserve University in Ohio, USA, and others conducted clinical studies using LITT to treat brain tumors, the results of which were published online April 2020 in World Neurosurgery.
-
Blast! Gilead Sciences or The $20 billion acquisition of Next Generation Antibody Drug Concedes (ADC) developer Immunomedics!
Time of Update: 2020-09-26
April, the company's first commercial ADC product, Trodelvy (sacituzumab govitecan-hziy), received accelerated FDA approval for adult patients with metastasis triple-negative breast cancer (mTNBC) who had previously received at least two treatments for metastasis diseases.
-
Then Le (Nirapali) first-line adaptive disease was approved! The only PARP inhibitor approved for first-line maintenance therapy in all populations of ovarian cancer.
Time of Update: 2020-09-26
Dr. Ying Du, founder, chairman and chief executive officer of Redding Pharmaceuticals, said, "Nirapali is the only one approved in China and around the world, and can be used as a single parp inhibitor for first-line and relapsed ovarian cancer maintenance treatment, regardless of the patient's biomarker status.
-
Innovative treatments for gastrointestinal cancer! Bronger Ingham pioneered RAILR2/CDH17 dual-specific antibody BI 905711 into human clinical trials!
Time of Update: 2020-09-26
() Original source: Boehringer Ingelheim Advanceds Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living With Gastrointestinal Cancers.
-
Light chain (AL) amyloid degeneration first treatment! Johnson and Johnson Darzalex Faspro Apply for New Allergies: Hematological Remission Rate Up to 92%
Time of Update: 2020-09-26
Darzalex is the world's first CD38-mediated, soluble cellular antibody drug, the first FDA-approved monoclonal antibody drug to treat multiple myeloma (MM), its intravenous preparation (IV) was launched in 2015, has become the backbone of clinical treatment MM therapy, widely used in first-line, second-line, multi-line therapy.
